BIIB

Biogen Stock Analysis

AI Rating

Good
  • Quality8/10
  • Growth 5/10
  • Value 5/10
Biogen sales and earnings growth
BIIB Growth
Neutral
  • Revenue Y/Y 2.22%
  • EPS Y/Y -21.23%
  • FCF Y/Y -22.47%
Biogen gross and profit margin trends
BIIB Profitability
Good
  • Gross margin 75.70%
  • EPS margin 13.10%
  • ROIC 5Y 13.55%
Biogen net debt vs free cash flow
BIIB Risk
Great
  • Debt / Equity 0.4
  • Debt / FCF 1.8
  • Interest coverage 999.0

Biogen stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - General stocks ↗